99mtc-depreotide tumour uptake in patients with non-hodgkin's lymphoma

Nuclear Medicine Communications

Volumn 25, Issue 8, 2004, Pages 839-843

  Bushnell, David L ^a   Menda, Yusuf ^a   Madsen, Mark T ^a   Link, Brian K ^a   Kahn, Daniel ^a   Truhlar, Scott M ^a   Juweid, Malik ^a   Shannon, Mary ^a   Murguia, Jeffrey S ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Lymphoma

Indexed keywords

DEPREOTIDE TC 99M; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX; IBRITUMOMAB IN 111; IBRITUMOMAB TIUXETAN; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; METABOLISM; METHODOLOGY; NONHODGKIN LYMPHOMA; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION STUDY; BONE MARROW; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; IMAGE ANALYSIS; RADIOACTIVITY; TUMOR LOCALIZATION;

HUMANS; LYMPHOMA, NON-HODGKIN; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 4143134188     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000126628.01919.f9     Document Type: Article

References (16)

1. Reubi JC, Waser B, van Hagen M, Lamberts SWJ. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992; 50:895-900.
2. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin-receptor imaging in lymphoma. Semin Nucl Med 1995; 25(3):262-271.
3. Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium-111-Pentetreotide uptake in endocrine tumors and lymphoma. J Nucl Med 1996; 37(6):916-922.
4. 99mTc-P829. J Cancer Res 1998; 58:1850-1859.
5. Nelson CA, Pearson DA, Wilson DM, Guaraldi MT, Moyer BR, Azure MT, et al. Biodistribution of a novel somatostatin receptor-binding peptide in rat pancreatic and human lung tumor murine xenografts. J Nucl Med 2000; 41(suppl):260P.
6. Morozumi T, Nakajima M, Ogawa K, Yuta S. Attenuation correction method using information of attenuation distribution for single photon CT. Med Imaging Tech 1984; 2:20-28.
7. Handmaker H, Lister-James J, Dann RW, Baran YM, Abernathy H. Scintigraphic assessment of Hodgkin's and non-Hodgkin's lymphoma patients with a novel SSTR binding peptide—Technetium Tc-99M P829. J Nucl Med 1997; 38(suppl):236P.
8. Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1995; 36(1):13-18.
9. Lugtenburg PJ, Lowenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphoma. J Nucl Med 2001; 42(2):222-229.
10. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43:1507-1529.
11. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993; 94:297-311.
12. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahbom M. Phase I/II Y-90 Zevalin (Yttrium-90 ibritumomab tiuxetan, IDEC Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27:766-777.
13. Slooter GD, Mearadji A, Breeman WAP, Marquet RL, de Jong M, Krenning EP, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001; 88:31-40.
14. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003; 30:9-15.
15. 188Re P2045 in primates as determined by necropsy and scintigraphic region of interest analysis biodistribution methods. J Nucl Med 2001; 42(5) (suppl):69P.
16. 188Re-P2045) in a small cell lung cancer (SCLC) mouse model. J Nucl Med 2002; 43(5) (Suppl):123P.